atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer Post published:July 1, 2022 Post category:Press Release
Algernon Pharmaceuticals Announces Pricing of Public Offering of Units Post published:June 29, 2022 Post category:Press Release
Tryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment Post published:June 29, 2022 Post category:Press Release
Mindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation Post published:June 29, 2022 Post category:Press Release
Optimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA Post published:June 29, 2022 Post category:Press Release
HAVN Life Enters Supply Agreement with MPB Group Inc. Post published:June 29, 2022 Post category:Press Release
PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of Shareholders Post published:June 29, 2022 Post category:Press Release
Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics Companies Protect Access to Abortion for Employees? Post published:June 27, 2022 Post category:Psychedelic Bulletin
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization Post published:June 27, 2022 Post category:Press Release